title: The effect of timing of iron supplementation on iron absorption and haemoglobin in post-malaria anaemia: a longitudinal stable isotope study in Malawian toddlers.
abstract: BACKGROUND
  In sub-Saharan Africa, children with Plasmodium falciparum malaria and anaemia are often given iron supplementation at the time of malaria treatment. Inflammation during and after malaria may decrease iron absorption, thus, absorption might be improved if the start of supplementation is delayed. The study objective was to measure iron absorption from iron supplements started immediately or delayed by two weeks after completion of therapy against uncomplicated P. falciparum malaria.
  
  
  METHODS
  Malawian toddlers (n=48; age 12-24 months) were alternatively assigned to two groups according to their appearance at the health centre: group A was provided iron supplements (30 mg Fe daily) as a FeSO4-containing syrup for eight weeks starting immediately after malarial treatment; group B was given the iron after a two-week delay. Iron absorption from the syrup was measured on the first day of iron supplementation, and after two and eight weeks in both groups. Haemoglobin (Hb), iron status and inflammation were assessed every two weeks. Fractional iron absorption at each time point and cumulative absorption was quantified by measuring erythrocyte incorporation of 57Fe and compared using mixed models.
  
  
  RESULTS
  Comparing group A and B, geometric mean iron absorption did not differ on the first day of supplementation (9.0% vs. 11.4%, P=0.213) and cumulative iron absorption from the three time points did not differ (6.0% vs. 7.2%, P=0.124). Hb concentration increased in both groups two weeks after malaria treatment (P<0.001) and did not differ after eight weeks of supplementation (P=0.542).
  
  
  CONCLUSIONS
  In anaemic toddlers after uncomplicated malaria, a two-week delay in starting iron supplementation did not significantly increase iron absorption or Hb concentration. Iron absorption is sufficiently high in the immediate post-malaria period to warrant supplementation. These findings suggest there is no need to change the current practice of immediate iron supplementation in this setting.
  
  
  BACKGROUND
  This trial was registered at Pan African Clinical Trials Registry (pactr.org) as PACTR2010050002141682.
authors.affiliation: From the Laboratory of Human Nutrition, Institute of Food, Nutrition and Health, ETH Zürich, Schmelzbergstrasse 7, LFV CH-8092 Zurich, Switzerland. dglinz@ethz.ch.
authors.forename: Dominik
authors.initials: D
authors.lastname: Glinz
authors.forename: Moses
authors.initials: M
authors.lastname: Kamiyango
authors.forename: Kamija S
authors.initials: KS
authors.lastname: Phiri
authors.forename: Francis
authors.initials: F
authors.lastname: Munthali
authors.forename: Christophe
authors.initials: C
authors.lastname: Zeder
authors.forename: Michael B
authors.initials: MB
authors.lastname: Zimmermann
authors.forename: Richard F
authors.initials: RF
authors.lastname: Hurrell
authors.forename: Rita
authors.initials: R
authors.lastname: Wegmüller
mesh_terms: D000740:Anemia / Q000188:drug therapy* / Q000453:epidemiology / Q000209:etiology*; D000962:Antimalarials / Q000627:therapeutic use; D005260:Female; D006454:Hemoglobins / Q000032:analysis*; D006801:Humans; D007223:Infant; D007249:Inflammation; D007501:Iron / Q000008:administration & dosage / Q000378:metabolism* / Q000627:therapeutic use*; D008137:Longitudinal Studies; D016778:Malaria, Falciparum / Q000150:complications* / Q000188:drug therapy / Q000453:epidemiology; D008295:Malawi / Q000453:epidemiology; D008297:Male
chemical_list: D000962:Antimalarials; D006454:Hemoglobins; D007501:Iron